AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials
Executive Summary
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
You may also be interested in...
AbbVie’s Q1 Revenue Growth Outpaces Big Pharma Peers
Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.
AbbVie Says “V” Is For V-Shaped Recovery
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.
AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.